ProPhase Labs (PRPH) Set to Announce Quarterly Earnings on Monday

ProPhase Labs (NASDAQ:PRPH) is expected to be posting its Q3 2026 results on Monday, November 16th. Analysts expect the company to announce earnings of $2.05 per share and revenue of $11.98 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 18, 2026 at 2:00 PM ET.

ProPhase Labs Trading Up 6.5%

ProPhase Labs stock traded up $0.00 during trading hours on Friday, reaching $0.00. The stock had a trading volume of 205,257 shares, compared to its average volume of 258,873. The stock has a market cap of $142,536.10, a PE ratio of -0.00 and a beta of 0.07. ProPhase Labs has a 52 week low of $0.00 and a 52 week high of $3.00. The company has a debt-to-equity ratio of 0.14, a current ratio of 0.14 and a quick ratio of 0.14. The company has a fifty day simple moving average of $0.01 and a 200-day simple moving average of $0.08.

ProPhase Labs Company Profile

ProPhase Labs, Inc. is a diversified healthcare company focused on diagnostics, genomics, and related healthcare services. Through its operating businesses, the company develops and provides clinical laboratory testing, genetic testing, and data-driven health solutions for consumers, healthcare providers, researchers, and pharmaceutical companies. ProPhase Labs’ activities have included molecular and genomic testing, clinical research support, and precision-health services. Its portfolio has also included Nebula Genomics, a genomics platform designed to provide whole-genome sequencing and enable individuals to manage and share their genetic data.